{"id":338569,"date":"2026-08-14T11:29:14","date_gmt":"2026-08-14T11:29:14","guid":{"rendered":"https:\/\/www.europesays.com\/se\/338569\/"},"modified":"2026-08-14T11:29:14","modified_gmt":"2026-08-14T11:29:14","slug":"blodtrycksmedicinen-som-flest-fortsatter-ta-ny-studie","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/se\/338569\/","title":{"rendered":"Blodtrycksmedicinen som flest forts\u00e4tter ta \u2013 ny studie"},"content":{"rendered":"<p>Efter fem \u00e5r tog 80 procent av dem som inlett behandlingen med s\u00e5 kallade angiotensinreceptorblockerare, ARB, fortfarande l\u00e4kemedlet regelbundet.<\/p>\n<p>\u201cDet vi kunde se \u00e4r att det b\u00e4sta \u00e4r att b\u00f6rja med mediciner i ARB-klassen. D\u00e4r slutar folk ta medicinen i mycket mindre utstr\u00e4ckning \u00e4n de andra klasserna av l\u00e4kemedel\u201d, s\u00e4ger <strong>Johan Sundstr\u00f6m<\/strong>, hj\u00e4rtl\u00e4kare och professor i epidemiologi till <a href=\"https:\/\/www.aftonbladet.se\/halsa\/a\/BxRRzE\/ny-studie-blodtrycksmedicinen-som-ar-bast-att-borja-med\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">Aftonbladet<\/a>.<\/p>\n<p><strong>MISSA INTE:<\/strong> <a href=\"https:\/\/www.news55.se\/samhalle\/news55-arrangerar-aldreriksdagen-2026-du-ar-inbjuden\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">News55 arrangerar \u00c4ldreriksdagen 2026 \u2013 Du \u00e4r inbjuden<\/a><\/p>\n<p>Avg\u00f6rande vilken blodtrycksmedicin de b\u00f6rjade anv\u00e4nda<\/p>\n<p>Studien fr\u00e5n Anders Wikl\u00f6f-institutet f\u00f6r hj\u00e4rtforskning vid Uppsala universitet omfattar \u00f6ver 340 000 personer. Forskarna har f\u00f6ljt patienterna under flera \u00e5r och j\u00e4mf\u00f6rt hur v\u00e4l de fortsatt med behandlingen beroende p\u00e5 vilken typ av blodtrycksmedicin de b\u00f6rjade anv\u00e4nda.<\/p>\n<p>N\u00e4st b\u00e4st resultat hade kalciumfl\u00f6desh\u00e4mmare. D\u00e4r fortsatte 65 procent regelbundet med medicinen efter fem \u00e5r.<\/p>\n<p>En m\u00f6jlig f\u00f6rklaring till skillnaden \u00e4r biverkningarna. Tidigare forskning har visat att ARB generellt ger f\u00e4rre biverkningar \u00e4n andra vanliga blodtrycksmediciner.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"576\" src=\"https:\/\/www.europesays.com\/se\/wp-content\/uploads\/2026\/08\/blodtryck-1024x576.png\" alt=\"\" class=\"wp-image-1197416\"  \/>N\u00e4rmare tre miljoner svenskar lever med h\u00f6gt blodtryck. Foto: Samuel Ste\u00e9n\/TT<\/p>\n<p>Traditionellt har m\u00e5nga patienter i st\u00e4llet f\u00e5tt b\u00f6rja med en ACE-h\u00e4mmare. ARB \u00e4r en nyare l\u00e4kemedelsgrupp och var fr\u00e5n b\u00f6rjan dyrare.<\/p>\n<p>Ett problem med ACE-h\u00e4mmare \u00e4r att vissa patienter drabbas av rethosta och d\u00e4rf\u00f6r beh\u00f6ver byta behandling.<\/p>\n","protected":false},"excerpt":{"rendered":"Efter fem \u00e5r tog 80 procent av dem som inlett behandlingen med s\u00e5 kallade angiotensinreceptorblockerare, ARB, fortfarande l\u00e4kemedlet&hellip;\n","protected":false},"author":2,"featured_media":338570,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[69],"tags":[9773,37335,113,112,8568,5783,21621,34,31,33,32,30],"class_list":["post-338569","post","type-post","status-publish","format-standard","has-post-thumbnail","category-halsa","tag-blodtryck","tag-blodtrycksmedicin","tag-halsa","tag-health","tag-hjart-och-karlsjukdomar","tag-hjarta","tag-hogt-blodtryck","tag-se","tag-svenska","tag-sverige","tag-sweden","tag-swedish"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@se\/117093634599019169","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/338569","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/comments?post=338569"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/338569\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media\/338570"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media?parent=338569"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/categories?post=338569"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/tags?post=338569"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}